Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENRY DAVID MITCHESON

Allopathic & Osteopathic Physicians Urology

NPI
1609878065
CMS profile
26956
Location
WATERTOWN, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$33.06

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $33.06 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $20.25 1
Antares Pharma, Inc. $12.81 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENRY DAVID MITCHESON

NPI 1609878065 · CMS profile ID 26956

Allopathic & Osteopathic Physicians / Urology

WATERTOWN, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609878065?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609878065?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609878065?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HENRY DAVID MITCHESON, NPI 1609878065, CMS profile ID 26956, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1609878065?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $33.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $20.2512/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 714876561 CMS
Antares Pharma, Inc. $12.8103/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676447783 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33.06 2
PY2020 $27.36 2
PY2021 $141.90 3
PY2023 $820.37 6
PY2025 $6,808.44 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $79,797.01 17
PY2024 Principal investigator $298,781.41 38
PY2023 Principal investigator $246,483.30 35
PY2022 Principal investigator $371,578.62 51
PY2021 Principal investigator $151,239.97 33
PY2020 Principal investigator $214,565.33 26
PY2019 Recipient $1,155.55 5
PY2019 Principal investigator $196,628.49 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $5,425.10 12/20/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112999
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 12/15/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112997
Principal investigator 1 ABBVIE INC. $6,830.00 12/04/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis;Bladder Pain Syndrome No dispute reported 06/30/2026 998409881
Principal investigator 1 ABBVIE INC. $2,320.00 11/21/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis;Bladder Pain Syndrome No dispute reported 06/30/2026 998408561
Principal investigator 1 ABBVIE INC. $2,400.00 11/08/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis;Bladder Pain Syndrome No dispute reported 06/30/2026 998407291
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $11,689.76 10/25/2023 Non-covered Recipient Entity
Bay State Clinical Trials Inc
C3300-201 No dispute reported 06/30/2026 1059417533
Principal investigator 1 ABBVIE INC. $3,792.89 10/04/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis;Bladder Pain Syndrome No dispute reported 06/30/2026 998402141
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $31,546.47 09/13/2023 Non-covered Recipient Entity
Bay State Clinical Trials Inc
C3300-201 No dispute reported 06/30/2026 1059417521
Principal investigator 1 ABBVIE INC. $2,395.00 09/05/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998398223
Principal investigator 1 ABBVIE INC. $1,340.92 08/09/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998394321
Principal investigator 1 ABBVIE INC. $8,140.00 07/18/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998391861
Principal investigator 1 ABBVIE INC. $3,000.00 07/18/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998391881
Principal investigator 1 ABBVIE INC. $7,278.84 07/03/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998388611
Principal investigator 1 Sumitomo Pharma America, Inc. $10,467.24 07/03/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112995
Principal investigator 1 Sumitomo Pharma America, Inc. $4,475.74 06/01/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112993
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,050.00 05/19/2023 Non-covered Recipient Entity
Bay State Clinical Trials Inc
C3300-201 No dispute reported 06/30/2026 1059417497
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,500.00 05/19/2023 Non-covered Recipient Entity
Bay State Clinical Trials Inc
C3300-201 No dispute reported 06/30/2026 1059417501
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $9,000.00 05/19/2023 Non-covered Recipient Entity
Bay State Clinical Trials Inc
C3300-201 No dispute reported 06/30/2026 1059419687
Principal investigator 1 ABBVIE INC. $5,811.14 05/04/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998381157
Principal investigator 1 Sumitomo Pharma America, Inc. $313.44 05/03/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112989
Principal investigator 1 Sumitomo Pharma America, Inc. $1,834.19 05/03/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112991
Principal investigator 1 Sumitomo Pharma America, Inc. $986.66 04/26/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112983
Principal investigator 1 Sumitomo Pharma America, Inc. $3,500.00 04/26/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112987
Principal investigator 1 Sumitomo Pharma America, Inc. $342.00 04/19/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS INC
A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder No dispute reported 06/30/2026 1146113001
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 04/06/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112985
Principal investigator 1 ABBVIE INC. $4,082.60 04/05/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998376673
Principal investigator 1 ABBVIE INC. $2,000.00 03/29/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998375911
Principal investigator 1 ABBVIE INC. $15,800.00 03/29/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998375913
Principal investigator 1 Sumitomo Pharma America, Inc. $34,240.87 03/23/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112977
Principal investigator 1 ABBVIE INC. $14,774.27 03/09/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998373589
Principal investigator 1 Sumitomo Pharma America, Inc. $11,079.55 03/01/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112979
Principal investigator 1 Sumitomo Pharma America, Inc. $16,460.18 03/01/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112981
Principal investigator 1 Sumitomo Pharma America, Inc. $3,719.25 02/09/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112975
Principal investigator 1 ABBVIE INC. $13,887.19 02/02/2023 Non-covered Recipient Entity
BAY STATE CLINICAL TRIALS
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) No dispute reported 06/30/2026 998368181
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 01/25/2023 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 1146112973